{"entity":{"type":"insider","cik":"0001626596","url":"/insider/0001626596","json_url":"/insider/0001626596.json","name":"Crestline Investors, Inc.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":9,"n_filings":9,"first":"2014-12-23","last":"2021-02-17","span_basis":"filed_date"},"name_variants":[{"name":"Crestline Investors, Inc.","source":"filing","n_filings":9,"first_seen":"2014-12-23","last_seen":"2021-02-17"}],"transactions":[{"id":5454916,"accession":"0000899243-21-007016","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-007016","line_url":"/filing/0000899243-21-007016#line-1","is_derivative":false,"issuer_cik":"0001281933","issuer_name":"Denali Therapeutics Inc.","issuer_ticker":"DNLI","issuer_name_source":null,"issuer_url":"/issuer/0001281933","owner_cik":null,"owner_name":"AKDL, L.P.; BRATTON DOUGLAS K; Crestline SI (GP), L.P.; Crestline Investors, Inc.; Crestline Management, LP","owner_display_name":"AKDL, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2216798.0,"shares_display":"2,216,798","price_per_share":65.0,"price_display":"65.00","price_state":"stated","total_value":144091870.0,"total_display":"144,091,870.00","total_whole":"144,091,870","shares_owned_after":9984836.0,"shares_owned_after_display":"9,984,836","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-02-12","filed_date":"2021-02-17","scope":"insider"},{"id":2045010,"accession":"0000899243-20-022430","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-022430","line_url":"/filing/0000899243-20-022430#line-1","is_derivative":false,"issuer_cik":"0001281933","issuer_name":"Denali Therapeutics Inc.","issuer_ticker":"DNLI","issuer_name_source":null,"issuer_url":"/issuer/0001281933","owner_cik":null,"owner_name":"Crestline Management, LP; Crestline Investors, Inc.; BRATTON DOUGLAS K; Crestline SI (GP), L.P.; AKDL, L.P.","owner_display_name":"Crestline Management, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1443247.0,"shares_display":"1,443,247","price_per_share":31.65,"price_display":"31.65","price_state":"stated","total_value":45678767.55,"total_display":"45,678,767.55","total_whole":"45,678,768","shares_owned_after":12201634.0,"shares_owned_after_display":"12,201,634","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-08-12","filed_date":"2020-08-14","scope":"insider"},{"id":2895213,"accession":"0000899243-20-015779","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-015779","line_url":"/filing/0000899243-20-015779#line-1","is_derivative":false,"issuer_cik":"0001281933","issuer_name":"Denali Therapeutics Inc.","issuer_ticker":"DNLI","issuer_name_source":null,"issuer_url":"/issuer/0001281933","owner_cik":null,"owner_name":"BRATTON DOUGLAS K; Crestline SI (GP), L.P.; Crestline Management, LP; AKDL, L.P.; Crestline Investors, Inc.","owner_display_name":"BRATTON DOUGLAS K","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1922855.0,"shares_display":"1,922,855","price_per_share":25.75,"price_display":"25.75","price_state":"stated","total_value":49513516.25,"total_display":"49,513,516.25","total_whole":"49,513,516","shares_owned_after":13644881.0,"shares_owned_after_display":"13,644,881","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-06-05","filed_date":"2020-06-09","scope":"insider"},{"id":2207166,"accession":"0000899243-20-006252","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-006252","line_url":"/filing/0000899243-20-006252#line-1","is_derivative":false,"issuer_cik":"0001281933","issuer_name":"Denali Therapeutics Inc.","issuer_ticker":"DNLI","issuer_name_source":null,"issuer_url":"/issuer/0001281933","owner_cik":null,"owner_name":"Crestline SI (GP), L.P.; AKDL, L.P.; Crestline Investors, Inc.; BRATTON DOUGLAS K; Crestline Management, LP","owner_display_name":"Crestline SI (GP), L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3894764.0,"shares_display":"3,894,764","price_per_share":20.25,"price_display":"20.25","price_state":"stated","total_value":78868971.0,"total_display":"78,868,971.00","total_whole":"78,868,971","shares_owned_after":15567736.0,"shares_owned_after_display":"15,567,736","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-02-26","filed_date":"2020-02-28","scope":"insider"},{"id":4257138,"accession":"0000899243-17-028694","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0000899243-17-028694","line_url":"/filing/0000899243-17-028694#line-7","is_derivative":false,"issuer_cik":"0001281933","issuer_name":"Denali Therapeutics Inc.","issuer_ticker":"DNLI","issuer_name_source":null,"issuer_url":"/issuer/0001281933","owner_cik":null,"owner_name":"Crestline Management, LP; Bratton Capital Inc.; Crestline Investors, Inc.; Bratton Capital Management, L.P.; BRATTON DOUGLAS K; AKDL, L.P.; Neuro Line Partners LP; Crestline SI (GP), L.P.","owner_display_name":"Crestline Management, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":275000.0,"shares_display":"275,000","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":4950000.0,"total_display":"4,950,000.00","total_whole":"4,950,000","shares_owned_after":19462499.0,"shares_owned_after_display":"19,462,499","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-12-12","filed_date":"2017-12-14","scope":"insider"},{"id":5157437,"accession":"0000899243-17-018338","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-17-018338","line_url":"/filing/0000899243-17-018338#line-1","is_derivative":false,"issuer_cik":"0001281933","issuer_name":"Juno Therapeutics, Inc.","issuer_ticker":"JUNO","issuer_name_source":null,"issuer_url":"/issuer/0001281933","owner_cik":null,"owner_name":"CL Alaska, L.P.; Crestline Management, LP; BRATTON DOUGLAS K; Crestline SI (GP), L.P.; Crestline Investors, Inc.","owner_display_name":"CL Alaska, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8000000.0,"shares_display":"8,000,000","price_per_share":27.0,"price_display":"27.00","price_state":"stated","total_value":216000000.0,"total_display":"216,000,000.00","total_whole":"216,000,000","shares_owned_after":9166130.0,"shares_owned_after_display":"9,166,130","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-07-13","filed_date":"2017-07-17","scope":"insider"},{"id":2625321,"accession":"0000899243-16-015213","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-16-015213","line_url":"/filing/0000899243-16-015213#line-1","is_derivative":false,"issuer_cik":"0001281933","issuer_name":"Juno Therapeutics, Inc.","issuer_ticker":"JUNO","issuer_name_source":null,"issuer_url":"/issuer/0001281933","owner_cik":null,"owner_name":"Crestline SI (GP), L.P.; BRATTON DOUGLAS K; CL Alaska, L.P.; Crestline Management, LP; Crestline Investors, Inc.","owner_display_name":"Crestline SI (GP), L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8600000.0,"shares_display":"8,600,000","price_per_share":39.0,"price_display":"39.00","price_state":"stated","total_value":335400000.0,"total_display":"335,400,000.00","total_whole":"335,400,000","shares_owned_after":17166130.0,"shares_owned_after_display":"17,166,130","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-03-01","filed_date":"2016-03-03","scope":"insider"},{"id":9269301,"accession":"0001209191-14-077894","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-14-077894","line_url":"/filing/0001209191-14-077894#line-1","is_derivative":false,"issuer_cik":"0001536054","issuer_name":"Juno Therapeutics, Inc.","issuer_ticker":"JUNO","issuer_name_source":null,"issuer_url":"/issuer/0001536054","owner_cik":null,"owner_name":"BRATTON DOUGLAS K; CL Alaska, L.P.; Crestline Investors, Inc.; Crestline Management, LP; Crestline SI (GP), L.P.","owner_display_name":"BRATTON DOUGLAS K","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":625000.0,"shares_display":"625,000","price_per_share":24.0,"price_display":"24.00","price_state":"stated","total_value":15000000.0,"total_display":"15,000,000.00","total_whole":"15,000,000","shares_owned_after":988398.0,"shares_owned_after_display":"988,398","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-12-23","filed_date":"2014-12-24","scope":"insider"},{"id":6297943,"accession":"0001209191-14-077779","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-14-077779","line_url":"/filing/0001209191-14-077779#line-1","is_derivative":false,"issuer_cik":"0001281933","issuer_name":"Juno Therapeutics, Inc.","issuer_ticker":"JUNO","issuer_name_source":null,"issuer_url":"/issuer/0001281933","owner_cik":null,"owner_name":"Crestline Management, LP; Crestline SI (GP), L.P.; BRATTON DOUGLAS K; Crestline Investors, Inc.; CL Alaska, L.P.","owner_display_name":"Crestline Management, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":625000.0,"shares_display":"625,000","price_per_share":25.0,"price_display":"25.00","price_state":"stated","total_value":15625000.0,"total_display":"15,625,000.00","total_whole":"15,625,000","shares_owned_after":988398.0,"shares_owned_after_display":"988,398","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-12-19","filed_date":"2014-12-23","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001714899","name":"Denali Therapeutics Inc.","url":"/issuer/0001714899","role":"Ten percent owner","n_filings":5,"first_seen":"2017-12-14","last_seen":"2021-02-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001594864","name":"Juno Therapeutics, Inc.","url":"/issuer/0001594864","role":"Ten percent owner","n_filings":4,"first_seen":"2014-12-23","last_seen":"2017-07-17"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001626596","retrieved_at":"2026-08-24T01:28:27+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}